News Archive

Recent results from DAPA-HF may be moving the treatment of heart failure into a new era of “quadruple therapy,” but further studies are needed to understand the benefits of using an SGLT2 inhibitor such as dapagliflozin in addition the guideline-recommended triple therapy, wrote the DCRI’s Michael Felker, MD, in a recent editorial in Circulation.

A study of proteins in plasma taken from patients in the IPF-PRO registry found that patients with IPF have a distinct circulating set of proteins and that select proteins correlate well with clini

Data monitoring committees (DMCs) play a critical role in clinical trials by protecting patients—especially in studies involving high-risk populations or potentially harmful treatments—and in order to fulfill this role successfully, these committees should have access to all data at each interim review, wrote the authors of a recent paper published in the Annals of Internal Medicine.

A new analysis of a DCRI study revealed that younger patients and older patients may need to undergo different types of testing for coronary artery disease in order to more accurately predict risk.

The DCRI served as the statistical and data coordinating center for ISCHEMIA, a late-breaking clinical trial that indicated invasive heart procedures may not reduce the chance of experiencing a maj

Researchers from the DCRI are optimistic about the opportunities that wearable devices present in caring for patients with heart failure; however, they also recognize that challenges must be overcome to successfully interpret and act upon patient data collected from wearables.

A DCRI-led study is the first to test the performance of the Pooled Cohort Risk Equations, a commonly used tool for assessing cardiovascular risk, in older adults.

The DCRI’s Sarah Armstrong, MD, served as the lead author for a policy statement and a co-author on a technical report advocating for more widespread use of bariatric and metabolic surgeries for ch

A recent study from DCRI researchers found that patients who have had strokes may receive different care than those who have had heart attacks, despite evidence that shows statins are effective for secondary prevention in both populations to prevent recurring ischemic events.

Mixed results from the CABANA trial have led to debate about whether catheter ablation is an effective treatment option that provides benefit to patients with atrial fibrillation.